Focus: Treeline Biosciences is a public-stage oncology biotech focused on molecularly validated but historically undruggable targets. Headquartered in San Diego with a lean pipeline of four Phase 1 programs, the company operates at pre-revenue scale.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Stable — net -4 jobs in 30d
3 added, 7 removed. Backfill posture.
Best suited for early-career scientists and clinicians seeking deep involvement in target validation and first-in-human oncology trials, accepting high technical and timeline risk in exchange for equity upside and structural stability post-merger.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Treeline Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Treeline Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Treeline Biosciences enters clinical trial collaboration with Roche - thepharmaletter.com
Treeline Biosciences enters clinical trial collaboration with Roche thepharmaletter.com
Stealthy startup Treeline plans a reverse merger - BioPharma Dive
Stealthy startup Treeline plans a reverse merger BioPharma Dive
Standard BioTools to merge with Treeline in biotech transformation deal - The Pharma Letter
Standard BioTools to merge with Treeline in biotech transformation deal The Pharma Letter
Standard BioTools and Treeline Biosciences Announce Merger Agreement - GlobeNewswire
Standard BioTools and Treeline Biosciences Announce Merger Agreement GlobeNewswire
Treeline merges with Standard, nabs lengthy cash runway for growing pipeline - FirstWord PHARMA
Treeline merges with Standard, nabs lengthy cash runway for growing pipeline FirstWord PHARMA
Novo underwhelmed by drug it once fought Pfizer for - STAT
Novo underwhelmed by drug it once fought Pfizer for STAT
Showing 6 of 7 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Application of modelling of cell monolayer permeation data to generate input parameters compatible with in vitro-in vivo translation of blood-brain-barrier disposition of drugs.
UDP-Glucuronosyl transferase mediated drug-drug interactions: An Industry perspective on recommended in vitro studies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo